These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 28092245)

  • 1. [Effect of the DiabetIMSS program on cardiovascular risk, blood pressure and HDL cholesterol in patients with metabolic syndrome].
    Mendoza-Romo MA; Montes-Acuña JF; Zavala-Cruz GG; Nieva-de Jesús RN; Ramírez-Arreola MC; Andrade-Rodríguez HJ
    Rev Med Inst Mex Seguro Soc; 2017; 55(1):32-39. PubMed ID: 28092245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglyceride-to-HDL-cholesterol ratio and metabolic syndrome as contributors to cardiovascular risk in overweight patients.
    Marotta T; Russo BF; Ferrara LA
    Obesity (Silver Spring); 2010 Aug; 18(8):1608-13. PubMed ID: 20019684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events.
    Mancia G; Bombelli M; Facchetti R; Casati A; Ronchi I; Quarti-Trevano F; Arenare F; Grassi G; Sega R
    J Hypertens; 2010 May; 28(5):999-1006. PubMed ID: 20308922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central blood pressure and pulse wave velocity: relationship to target organ damage and cardiovascular morbidity-mortality in diabetic patients or metabolic syndrome. An observational prospective study. LOD-DIABETES study protocol.
    Gómez-Marcos MA; Recio-Rodríguez JI; Rodríguez-Sánchez E; Castaño-Sánchez Y; de Cabo-Laso A; Sánchez-Salgado B; Rodríguez-Martín C; Castaño-Sánchez C; Gómez-Sánchez L; García-Ortiz L
    BMC Public Health; 2010 Mar; 10():143. PubMed ID: 20298558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent high prevalence of cardiovascular risk factors in the urban middle class in India: Jaipur Heart Watch-5.
    Gupta R; Sharma KK; Gupta A; Agrawal A; Mohan I; Gupta VP; Khedar RS; Guptha S
    J Assoc Physicians India; 2012 Mar; 60():11-6. PubMed ID: 22799108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten years cardiovascular risk estimation according to Framingham score and non HDL-cholesterol in blood donors.
    Graffigna MN; Berg G; Migliano M; Salgado P; Soutelo J; Musso C
    Diabetes Metab Syndr; 2015; 9(1):24-7. PubMed ID: 25470632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-high-density-lipoprotein cholesterol and cardiovascular risk factors among adolescents with and without impaired fasting glucose.
    Liu J; Joshi D; Sempos CT
    Appl Physiol Nutr Metab; 2009 Apr; 34(2):136-42. PubMed ID: 19370043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2).
    Cheung BM; Wat NM; Man YB; Tam S; Cheng CH; Leung GM; Woo J; Janus ED; Lau CP; Lam TH; Lam KS
    Am J Hypertens; 2008 Jan; 21(1):17-22. PubMed ID: 18091739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease risk factors in youth with type 1 and type 2 diabetes: implications of a factor analysis of clustering.
    Mayer-Davis EJ; Ma B; Lawson A; D'Agostino RB; Liese AD; Bell RA; Dabelea D; Dolan L; Pettitt DJ; Rodriguez BL; Williams D;
    Metab Syndr Relat Disord; 2009 Apr; 7(2):89-95. PubMed ID: 18847385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
    Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
    Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial to assess pharmacist- physician collaborative practice in the management of metabolic syndrome in a university medical clinic in Jordan.
    Hammad EA; Yasein N; Tahaineh L; Albsoul-Younes AM
    J Manag Care Pharm; 2011 May; 17(4):295-303. PubMed ID: 21534640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White fish reduces cardiovascular risk factors in patients with metabolic syndrome: the WISH-CARE study, a multicenter randomized clinical trial.
    Vázquez C; Botella-Carretero JI; Corella D; Fiol M; Lage M; Lurbe E; Richart C; Fernández-Real JM; Fuentes F; Ordóñez A; de Cos AI; Salas-Salvadó J; Burguera B; Estruch R; Ros E; Pastor O; Casanueva FF;
    Nutr Metab Cardiovasc Dis; 2014 Mar; 24(3):328-35. PubMed ID: 24462043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic syndrome in type 2 diabetic subjects in Gorgan, Iran.
    Marjani A; Mojerloo M
    J Pak Med Assoc; 2011 May; 61(5):458-61. PubMed ID: 22204179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of metabolic syndrome profile on cardiovascular risk.
    Mitu F; Cobzaru R; Leon MM
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):308-14. PubMed ID: 24340509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum total and high-density lipoprotein phospholipids: independent predictive value for cardiometabolic risk.
    Onat A; Altuğ Çakmak H; Can G; Yüksel M; Köroğlu B; Yüksel H
    Clin Nutr; 2014 Oct; 33(5):815-22. PubMed ID: 24246837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the hypothalamic-pituitary-adrenal axis dysregulation on the metabolic profile of patients affected by diabetes mellitus-associated late onset hypogonadism.
    Tirabassi G; Chelli FM; Ciommi M; Lenzi A; Balercia G
    Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):53-9. PubMed ID: 26643209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome.
    Opie LH
    Circulation; 2007 Jan; 115(3):e32-5. PubMed ID: 17242286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.